Qiu Min, Fu Qin, Jiang Chunjie, Liu Da
Department of Orthopedics, Shengjing Hospital of China Medical University, Shenyang, China.
Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Front Genet. 2020 Nov 12;11:615864. doi: 10.3389/fgene.2020.615864. eCollection 2020.
MicroRNAs (miRNAs) have been shown to play important roles in many cancers, including breast cancer. The majority of previous studies employed network analysis to identify key miRNAs in cancer progression. However, most of dysregulated miRNA networks were constructed based on the expression variation of miRNAs and target genes.
The relations between miRNAs and target genes were computed by Spearman correlation separately in breast cancer and normal breast samples. We calculated dysregulated scores based on the dysregulation of miRNA-mRNA regulatory relations. A dysregulated miRNA target network (DMTN) was constructed from the miRNA-mRNA pairs with significant dysregulated scores. SVM classifier was employed to predict breast cancer risk miRNAs from the DMTN. Hypermetric test was utilized to calculate the significance of overlap between different gene sets. Pearson correlation was used to evaluate associations between miRNAs/genes and drug response.
The DMTN comprised 511 miRNAs and was similar to common biological networks. Based on miRNAs and target genes in DMTN, we predicted 90 breast cancer risk miRNAs by using SVM classifier. Predicted risk miRNAs and one-step neighbor genes were significantly overlapping with differential miRNAs, cancer-related and housekeeping genes in breast cancer. These risk miRNAs were involved in many cancer-related and immune-related processes. In addition, most risk miRNAs were able to predict survival of breast cancer patients. More interestingly, some risk miRNAs and one-step neighbor genes were remarkably associated with immune cell infiltration. For example, high expression of hsa-miR-155 indicates high abundance of activated CD4+ T cells but low level of M2 macrophage infiltration. Furthermore, we identified 588 miRNA-drug and 3,146 gene-drug pairs, wherein the expression level of miRNAs/genes could indicate the sensitivity of cancer cells to anti-cancer drugs.
We predicted 90 breast cancer risk miRNAs based on proposed DMTN by using SVM classifier. Predicted risk miRNAs are biologically and clinically relevant in breast cancer. Risk miRNAs and one-step neighbor genes could serve as biomarkers for immune cell infiltration and anti-cancer drug response, which sheds lights on immunotherapy or targeted therapy for patients with breast cancer.
微小RNA(miRNA)已被证明在包括乳腺癌在内的多种癌症中发挥重要作用。此前的大多数研究采用网络分析来识别癌症进展中的关键miRNA。然而,大多数失调的miRNA网络是基于miRNA和靶基因的表达变化构建的。
分别在乳腺癌和正常乳腺样本中通过Spearman相关性计算miRNA与靶基因之间的关系。我们基于miRNA- mRNA调控关系的失调计算失调分数。从具有显著失调分数的miRNA- mRNA对构建失调的miRNA靶标网络(DMTN)。采用支持向量机(SVM)分类器从DMTN中预测乳腺癌风险miRNA。利用超几何检验计算不同基因集之间重叠的显著性。采用Pearson相关性评估miRNA/基因与药物反应之间的关联。
DMTN包含511个miRNA,与常见生物网络相似。基于DMTN中的miRNA和靶基因,我们使用SVM分类器预测了90个乳腺癌风险miRNA。预测的风险miRNA及其一步邻近基因与乳腺癌中的差异miRNA、癌症相关基因和管家基因显著重叠。这些风险miRNA参与了许多癌症相关和免疫相关过程。此外,大多数风险miRNA能够预测乳腺癌患者的生存情况。更有趣的是,一些风险miRNA及其一步邻近基因与免疫细胞浸润显著相关。例如,hsa-miR-155的高表达表明活化的CD4 + T细胞丰度高,但M2巨噬细胞浸润水平低。此外,我们鉴定出588个miRNA-药物对和3146个基因-药物对,其中miRNA/基因的表达水平可表明癌细胞对抗癌药物的敏感性。
我们使用SVM分类器基于所提出的DMTN预测了90个乳腺癌风险miRNA。预测的风险miRNA在乳腺癌中具有生物学和临床相关性。风险miRNA及其一步邻近基因可作为免疫细胞浸润和抗癌药物反应的生物标志物,为乳腺癌患者的免疫治疗或靶向治疗提供了线索。